



20 February 2017

Via E-Lodgment

Manager of Company Announcements
ASX Limited
Level 6, 20 Bridge Street
Sydney, NSW 2000

NOTICE OF CHANGE OF INTERESTS OF SUBSTANTIAL HOLDER

REVA Medical, Inc. (ASX: RVA) (“**Company**”) announces that in accordance with the Deed of Undertaking entered into between the Company and ASX, the Company provides ASX with the following information in relation to the following change in substantial holding in the Company.

1 Details of Substantial Holder

Name:	Senrigan Master Fund
ACN/ARSN (if applicable):	N/A
Date of change in the interests of the Substantial Holder:	13 July 2016
The previous notice was provided to ASX on:	16 February 2016

2 Previous and Present Voting Power

The total number of votes attached to all voting shares in the Company that the substantial holder or its associates had a relevant interest in when last required, and when now required, to give a substantial holder notice, are as follows:

Class of Securities	Previous Notice			Present Notice		
	Number of Securities	Person's Votes *	Voting Power *	Number of Securities	Person's Votes *	Voting Power *
Common Stock (each share of Common Stock is equivalent to 10 CHESS Depository Interests (“CDIs”))	5,765,230 (equivalent to 57,652,300 CDIs)	5,765,230	13.6%	6,219,271 (equivalent to 62,192,706 CDIs)	6,219,271	14.5%

* The number of votes held by the substantial holder and the substantial holder’s voting power is calculated on the basis that all CDIs were held as shares of common stock. Each share of common stock represents ten CDIs.

3 Details of Present Registered Holders

The persons registered as holders of the securities referred to above are as follows:

Holder of Relevant Interest	Registered Holder of Securities	Class and Number of Securities
Senrigan Master Fund **	N/A	6,219,271 shares of Common Stock (equivalent to 62,192,706 CDIs)

** Senrigan Capital Management Limited, a Cayman Islands limited company, advises and is the investment manager to Senrigan Master Fund, who controls the securities.

Katrina Thompson
Company Secretary
20 February 2017

About REVA

REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable scaffolds, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s *Fantom*[®] scaffold has been designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require regulatory approval before it can commercialize *Fantom* or any other product.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to obtain regulatory approvals, timely and successfully complete our clinical trials, protect our intellectual property position, commercialize our products if and when approved, develop and commercialize new products, recruit and retain our key personnel, and estimates regarding our capital requirements and financial performance. You should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on March 10, 2016, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

**United States
Investor & Media Enquiries:**
REVA Medical, Inc.
Cheryl Liberatore
Director, Communications
+1 858-966-3045

**Australia
Investor Enquiries:**
Inteq Limited
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

**Australia
Media Enquiries:**
Buchan Consulting
Rebecca Wilson
+61 3 9866 4722

HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 • +1 (858) 966-3000 • +1 (858) 966-3099 (FAX) • www.revamedical.com

AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O'Connell Street, Sydney NSW 2000 • +61 2 9237 2800

ARBN 146 505 777 • REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability